These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

392 related items for PubMed ID: 20489416

  • 21. Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.
    Velussi M.
    Nutr Metab Cardiovasc Dis; 2002 Feb; 12(1):29-35. PubMed ID: 12125227
    [Abstract] [Full Text] [Related]

  • 22. Residual dyslipidaemia after statin treatment in France: Prevalence and risk distribution.
    Ferrières J, Bérard E, Crisan O, Bongard V.
    Arch Cardiovasc Dis; 2010 May; 103(5):302-9. PubMed ID: 20619240
    [Abstract] [Full Text] [Related]

  • 23. A case report of a diabetic woman with very low HDL cholesterol.
    Chaychi L, Kinlaw WB, Asztalos BF, Schaefer EJ.
    J Clin Lipidol; 2010 May; 4(2):133-5. PubMed ID: 21122641
    [No Abstract] [Full Text] [Related]

  • 24. Low- and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2.
    Santos RD, Waters DD, Tarasenko L, Messig M, Jukema JW, Ferrières J, Verdejo J, Chiang CW, L-TAP 2 Investigators.
    Am Heart J; 2009 Nov; 158(5):860-6. PubMed ID: 19853709
    [Abstract] [Full Text] [Related]

  • 25. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
    Cardenas GA, Lavie CJ, Cardenas V, Milani RV, McCullough PA.
    Rev Cardiovasc Med; 2008 Nov; 9(4):239-58. PubMed ID: 19122582
    [Abstract] [Full Text] [Related]

  • 26. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M, Sazonov V, Gutkin SW, Hokanson JE.
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
    [Abstract] [Full Text] [Related]

  • 27. Fibrate therapy in the management of dyslipidemias, alone and in combination with statins: role of delayed-release fenofibric acid.
    Schima SM, Maciejewski SR, Hilleman DE, Williams MA, Mohiuddin SM.
    Expert Opin Pharmacother; 2010 Apr; 11(5):731-8. PubMed ID: 20210682
    [Abstract] [Full Text] [Related]

  • 28. Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk.
    Stalenhoef AF, Davidson MH, Robinson JG, Burgess T, Duttlinger-Maddux R, Kallend D, Goldberg AC, Bays H.
    Diabetes Obes Metab; 2012 Jan; 14(1):30-9. PubMed ID: 21819519
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy.
    Alagona P.
    Am J Manag Care; 2009 Mar; 15(3 Suppl):S65-73. PubMed ID: 19355805
    [Abstract] [Full Text] [Related]

  • 37. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).
    May HT, Anderson JL, Pearson RR, Jensen JR, Horne BD, Lavasani F, Yannicelli HD, Muhlestein JB.
    Am J Cardiol; 2008 Feb 15; 101(4):486-9. PubMed ID: 18312763
    [Abstract] [Full Text] [Related]

  • 38. High-density lipoprotein as a therapeutic target: clinical evidence and treatment strategies.
    Toth PP.
    Am J Cardiol; 2005 Nov 07; 96(9A):50K-58K; discussion 34K-35K. PubMed ID: 16291015
    [Abstract] [Full Text] [Related]

  • 39. Blood lipids in 75,048 type 2 diabetic patients: a population-based survey from the Swedish National diabetes register.
    Eriksson M, Zethelius B, Eeg-Olofsson K, Nilsson PM, Gudbjörnsdottir S, Cederholm J, Eliasson B.
    Eur J Cardiovasc Prev Rehabil; 2011 Feb 07; 18(1):97-105. PubMed ID: 21354969
    [Abstract] [Full Text] [Related]

  • 40. [Therapeutic approach to dyslipidemia and goal achievement in a Spanish population with type 2 diabetes without cardiovascular disease].
    Pérez A, González Blanco C, Hernández-Presa MÁ, Chaves J.
    Endocrinol Nutr; 2011 Feb 07; 58(6):283-90. PubMed ID: 21641286
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.